STAT+: Pharmalittle: Sanofi scraps rare-disease drug deal under FTC pressure; patients regain weight after stopping Lilly’s Zepbound
STAT
DECEMBER 12, 2023
As for us, we are as busy as ever hunting and gathering items of interest. The data, which represents the full results from an 88-week study funded by the company, suggests that people have to stay on the weekly injection if they want to maintain significant weight loss. We trust you have your own hectic agendas.
Let's personalize your content